Sell 1/28/2025Upgraded
Recursion Pharmaceuticals, Inc. (RXRX) was upgraded to D- from E+ on 1/28/2025 due to an increase in the total return index, valuation index and volatility index.

Sell 1/13/2025Downgrade
Recursion Pharmaceuticals, Inc. (RXRX) was downgraded to E+ from D- on 1/13/2025 due to a decline in the valuation index.

Sell 12/27/2024Upgraded
Recursion Pharmaceuticals, Inc. (RXRX) was upgraded to D- from E+ on 12/27/2024 due to an increase in the valuation index, volatility index and total return index.

Sell 12/12/2024Downgrade
Recursion Pharmaceuticals, Inc. (RXRX) was downgraded to E+ from D- on 12/12/2024 due to a decline in the valuation index.

Sell 11/27/2024Upgraded
Recursion Pharmaceuticals, Inc. (RXRX) was upgraded to D- from E+ on 11/27/2024 due to an increase in the valuation index.

Sell 11/12/2024Downgrade
Recursion Pharmaceuticals, Inc. (RXRX) was downgraded to E+ from D- on 11/12/2024 due to a decline in the total return index, solvency index and valuation index. The quick ratio declined from 5.54 to 3.95.

Sell 8/15/2024Upgraded
Recursion Pharmaceuticals, Inc. (RXRX) was upgraded to D- from E+ on 8/15/2024 due to an increase in the valuation index.

Sell 3/28/2024Downgrade
Recursion Pharmaceuticals, Inc. (RXRX) was downgraded to E+ from D- on 3/28/2024 due to a decline in the valuation index and volatility index.

Sell 2/12/2024Upgraded
Recursion Pharmaceuticals, Inc. (RXRX) was upgraded to D- from E+ on 2/12/2024 due to a noticeable increase in the total return index and volatility index.

Sell 12/15/2023Downgrade
Recursion Pharmaceuticals, Inc. (RXRX) was downgraded to E+ from D- on 12/15/2023 due to a noticeable decline in the total return index and volatility index.

Sell 8/28/2023Upgraded
Recursion Pharmaceuticals, Inc. (RXRX) was upgraded to D- from E+ on 8/28/2023 due to a large increase in the total return index and volatility index.

Sell 3/20/2023Downgrade
Recursion Pharmaceuticals, Inc. (RXRX) was downgraded to E+ from D- on 3/20/2023 due to a decline in the total return index and volatility index.

Sell 3/14/2023Downgrade
Recursion Pharmaceuticals, Inc. (RXRX) was downgraded to D- from D on 3/14/2023 due to a decline in the total return index, growth index and volatility index. EBIT declined 1.94% from -$62.57M to -$63.79M.

Sell 2/9/2023Upgraded
Recursion Pharmaceuticals, Inc. (RXRX) was upgraded to D from E+ on 2/9/2023 due to an increase in the valuation index.

Sell 2/8/2023Downgrade
Recursion Pharmaceuticals, Inc. (RXRX) was downgraded to E+ from D on 2/8/2023 due to a decline in the solvency index and valuation index. Debt to equity increased from 0.01 to 0.02.

Sell 6/17/2022Upgraded
Recursion Pharmaceuticals, Inc. (RXRX) was upgraded to D from D- on 6/17/2022 due to an increase in the volatility index.

Sell 5/31/2022Upgraded
Recursion Pharmaceuticals, Inc. (RXRX) was upgraded to D- from E+ on 5/31/2022 due to an increase in the valuation index.

Sell 5/13/2022Downgrade
Recursion Pharmaceuticals, Inc. (RXRX) was downgraded to E+ from D- on 5/13/2022 due to a noticeable decline in the solvency index, valuation index and volatility index. The quick ratio declined from 11.27 to 7.03.

Sell 5/5/2022Upgraded
Recursion Pharmaceuticals, Inc. (RXRX) was upgraded to D- from E+ on 5/5/2022 due to an increase in the valuation index.

Sell 4/20/2022Downgrade
Recursion Pharmaceuticals, Inc. (RXRX) was downgraded to E+ from D- on 4/20/2022 due to a decline in the total return index.

Sell 4/18/2022Downgrade
Recursion Pharmaceuticals, Inc. (RXRX) was downgraded to D- from D on 4/18/2022 due to a substantial decline in the efficiency index, total return index and volatility index. Net income declined 36.91% from -$47.43M to -$64.93M, and total capital declined 9.36% from $599.78M to $543.66M.

Sell 8/13/2021None
Recursion Pharmaceuticals, Inc. (RXRX) was downgraded to D from U on 08/13/2021.